Abstract
The effectiveness of combination chemotherapy with mitomycin-C (MMC) plus futraful (N1-(2′-tetrahydrofuryl)-5-fluorouracil), as an adjunct to surgery for gastric cancer was investigated in a prospective randomized controlled study. Three thousand and thirty-three Japanese patients in 344 hospitals were entered and 2873 could be followed for 5 years. All patients had undergone gastrectomy from April 1977 to May 1979 and were assigned, at random, to either Groups A, B or C. In Group A, bolus MMC was administered with no further treatment. In Group C, oral futraful was given for one year, without MMC induction. In Group B, both a bolus MMC injection and oral futraful were prescribed. This randomized study showed no statistical difference in the 5 year survival rate among the three groups. However, in patients given MMC and put on oral futraful for one year, the 5 year survival rate for those with stage III gastric cancer or for those with positive lymphnode metastasis plus obvious serosal invasion seemed to be improved.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Inokuchi K, Hattori T, Taguchi T, Abe O, Ogawa N. Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years. Cancer 1984; 53: 2393–2397.
Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery. Jpn J Surg 1973; 3: 61–71.
Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chron Dis 1958; 9: 699–713.
Breslow N. A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika 1970; 57: 579–594.
Miwa K. Cancer of the stomach in Japan. Gann Monograph on Cancer Research 1979; 22: 61–75.
Jinnai D, Higashi H. Extended radical operation with preoperative chemotherapy for gastric cancer. Gann Monograph on Cancer Research 1976; 18: 111–119.
Imanaga H, Nakazato H. Results of surgery for gastric cancer and effect of adjuvant Mitomycin-C on cancer recurrence. World J Surg 1977; 1: 213–221.
Hattori T, Mori A, Hirata K, Ito I. Five year survival rate of gastric cancer patients treated by gastrectomy, large dose of Mitomycin-C and/or allogeneic bone marrow transplantation. Gann 1972; 63: 517–522.
Kano T, Kumashiro R, Tamada R, Inokuchi K. Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach. Jpn J Surg 1981; 11: 291–298.
Shabel FM. The use of tumor growth kinetics in planning “curative” chemotherapy of advanced solid tumors. Cancer Res 1969; 29: 2384–2389.
Hattori T, Niimoto M, Nakano A, Oride M, Takiyama W, Nishimawari K. Postoperative long term immunochemotherapy with Mitomycin-C, PSK and FT-207 in gastric cancer patients. Jpn J Surg 1979; 9: 110–117.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hattori, T., Inokuchi, K., Taguchi, T. et al. Postoperative adjuvant chemotherapy for gastric cancer, the second report. Analysis of data on 2873 patients followed for five years. The Japanese Journal of Surgery 16, 175–180 (1986). https://doi.org/10.1007/BF02471090
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02471090